期刊文献+

急性冠脉综合征患者早期强化调脂治疗的疗效观察 被引量:9

Effect of Early Intensive Lipid-lowering Treatment on Acute Coronary Syndrome
下载PDF
导出
摘要 目的:研究急性冠脉综合征患者早期强化调脂治疗的疗效。方法:69例急性冠脉综合征患者随机分为两组,在常规治疗的基础上,强化组入院时立即给予阿托伐他汀40mg口服,之后每晚口服40mg 3个月,对照组常规给予每晚口服阿托伐他汀20mg 3个月。监测入院时及治疗3个月后的TC、LDL-C、HDL-C、TG、CRP、ALT、AST水平,并随访一年的心绞痛发生率、(再发)心肌梗死发生率、心源性猝死发生率。结果:对照组入院时及治疗3个月后的TC、LDL-C、HDL-C、TG、CRP水平分别为:5.53±0.55mmoL/L、4.51±0.39mmoL/L、3.78±0.33mmoL/L、2.76±0.28mmoL/L、0.81±0.24 mmoL/L、1.05±0.22 mmoL/L、2.56±0.38mmoL/L、1.83±0.22mmoL/L、2.14±0.49mmoL/L、0.79±0.32mmoL/L;相应的强化组结果为:5.89±0.49mmoL/L、4.07±0.35mmoL/L、3.91±0.43mmoL/L、2.49±0.23mmoL/L、0.76±0.19mmoL/L、1.08±0.20mmoL/L、2.33±0.22mmoL/L、1.68±0.17mmoL/L、1.99±0.57mmoL/L、0.67±0.26mmoL/L;随访一年,对照组的心绞痛发生率、(再发)心肌梗死发生率、心源性猝死率为36.4%、17.4%、12.1%,强化组相应为:25%、8.7%、5.6%,两组相比差异有显著性。结论:急性冠脉综合征患者早期强化调脂治疗能更好的降低TC、LDL-C、TG、CRP水平,升高HDL-C水平,降低心血管不良事件发生率,并具有良好的安全性。 Objective: To observe the effect of early intensive lipid lowering treatment on the patients with acute coronary syndrome.Method: 69 patients with acute coronary syndrome were divided into two groups randomly.Conventional treatments were given in both groups.Simvastatin 40mg were given while the patients were in hospital at once,and 40mg qn for 3 months in the intensive group;Simvastatin 20mg qn were given in the convention group.The total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),triglyceride(TG),high density lipoprotein cholesterol(HDL-C),C-reactive protein(CRP),alanine aminotransferase(ALT) and aspartate aminotransferase(AST) levels were observed before treatment and at the end of 3 months after treatment in both groups.Main cardiovascular events were observed also.Result: The TC,LDL-C,CRP,TG before treatment and at the end of 3 months after treatment in convention group were 5.53±0.55mmoL/L、4.51±0.39mmoL/L 、3.78±0.33mmoL/L、2.76±0.28mmoL/L 、0.81±0.24 mmoL/L、1.05±0.22 mmoL/L、2.56±0.38mmoL/L、1.83±0.22mmoL/L、2.14±0.49mmoL/L、0.79±0.32mmoL/L;while those were 5.89±0.49mmoL/L、4.07±0.35mmoL/L、3.91±0.43mmoL/L、2.49±0.23mmoL/L、0.76±0.19mmoL/L、1.08±0.20mmoL/L、2.33±0.22mmoL/L、1.68±0.17mmoL/L、1.99±0.57mmoL/L、0.67±0.26mmoL/L in the intensive group;The rate of angina,myocardial infarction,and sudden cardiac death in the convention group were 52.2%,34.8%,26.1%;while they were 26.1%,8.7%,4.3% in the intensive group.Conclusion: It can decrease the rates of cardiovascular events by the early intensive lipid lowering treatment on acute coronary syndrome patients,and the intensive dose is feasible and safe.
作者 朱青
出处 《河北医学》 CAS 2011年第1期35-37,共3页 Hebei Medicine
关键词 急性冠脉综合征 调脂治疗 Acute coronary syndrome Lipid-lowering treatment
  • 相关文献

参考文献6

  • 1Schoonjans K, Peinado-Onsurbe J, Fruchart JC, et al. 3- Hydroxy-3-methylglutaryl CoA reduetase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase[ J ]. FEBS Lett, 2005,452 (3) : 160-164. 被引量:1
  • 2Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans [ J ]. Circulation , 2005,111 (18) :2356-2363. 被引量:1
  • 3Hoye A, Tanabe K, Lemos PA, et al. Significant reduction in restenosis after the use of sirolimuseluting stents in the treatment of chronic total occlusions [ J ]. Am Coll Cardiol, 2004,43( 11 ) :1954-1958. 被引量:1
  • 4Van Wissen S, Trip MD, Smilde TJ, et al. Differential hs- CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy [ J ]. Atherosclerosis ,2006,165 ( 2 ) :361-366. 被引量:1
  • 5Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial[ J]. JAMA ,200,285 ( 13 ) : 1711 - 1718. 被引量:1
  • 6Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines [ J ]. Circulation,2004,110 ( 6 ) :763. 被引量:1

同被引文献64

  • 1刘怀昌,严俊儒,徐宁.阿托伐他汀与氟伐他汀对老年高脂血症强化降脂治疗的疗效和安全性观察[J].中国现代医学杂志,2005,15(14):2205-2207. 被引量:8
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2136
  • 3Sehoonjans K, Peinado-Onsurbe J, Fruehart JC, et al. 3-Hydroxy-3- methylglutaryl CoA reductase inhibitors reduce serum triglyeefide lev- els through modulation of apolipoproteirt C-Ill and lipoprotein lipase [J]. FEBS Lett,2005,452(3) :160 - 164. 被引量:1
  • 4Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe:pleiotropic and lipid--lowering effects on endothelial func- tion in humans [ J ]. Circulation ,2005,111 ( 18 ) :2356 - 2363. 被引量:1
  • 5Reddy R, Chahoud G, Mehta JL. Modulation of cardiovascular remode- ling with statins : fact or fiction [ J ] . Curt Vasc Pharmacol, 2005,3 : 69 - 79. 被引量:1
  • 6Hong Y J, Jeong MH, Hyun DW,et al. Prognostics significance of simv- astatin therapy in with ischemic heart failure who underwent pcrcuta- neous coronary intervention for acute myocardial infarction [ J ]. Am J Cardio1,2005 ,95 :619 - 622. 被引量:1
  • 7Pasceri V, Patti G, Nusca A, et al. The ARMYDA Investigators random- ized trial of atorvastatin for reduction of myocardial damage during cor- onary intervention : Results from the ARMYDA ( atorvastatin for reduc- tion of myocardial damage during angioplasty)study [ J ]. Circulation, 2004,110(6) :674. 被引量:1
  • 8Okazaki S. Early statin treatment inpatients with acute coronary syn- drome (ESTABLISH) [J]. Circulation,2004,110(6) :1061 - 1068. 被引量:1
  • 9Petrenio A, Amoroso G, ljrnbnmo U, et al. Simvastatin does not inhibit informal hyperplasia and restenosis but promotes plaque regression in normoeholestemlemic patients undergoing coronary stenting:A random- ized study with intravascular ultrasound [ J ]. Am H J, 2005, 149 (3) :520. 被引量:1
  • 10Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines [ J ]. Circulation, 2004,110 ( 6 ) : 763. 被引量:1

引证文献9

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部